Skip to main content
$4.03 -$0.08 (-1.9%)

04:00 PM EST on 02/01/23

Assertio Holdings, Inc. (NASDAQ:ASRT)

CAPS Rating: 5 out of 5

A specialty pharmaceutical company focused on the development and commercialization of differentiated products that address growing markets and are based on proprietary oral drug delivery technologies.

Current Price $4.03 Mkt Cap $198.5M
Open $4.16 P/E Ratio 7.25
Prev. Close $4.03 Div. (Yield) $0.00 (0.0%)
Daily Range $4.02 - $4.21 Volume 709,467
52-Wk Range $1.86 - $4.44 Avg. Daily Vol. 1,139,020

Caps

How do you think NASDAQ:ASRT will perform against the market?

Add Stock to CAPS Watchlist

All Players

246 Outperform
13 Underperform
 

All-Star Players

28 Outperform
1 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:ASRT Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

VladimirPoutine (< 20)
Submitted February 06, 2022

Turn around and highly profitable.

ssbb123 (27.90)
Submitted February 22, 2010

"Cancer risk" can't see this being a good investment for the next few months at least.http://www.forbes.com/2010/02/18/xenoport-glaxosmithkline-depomed-markets-equities-pharmaceuticals.html?partner=yahootix

Recent Community Commentary

Read the most recent pitches from players about ASRT.

Recs

0
Member Avatar XMFFlygal (95.08) Submitted: 12/14/2022 11:59:10 PM : Outperform Start Price: $3.82 NASDAQ:ASRT Score: +1.32

Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it is raising its outlook for 2022 full-year net product sales to greater than $152 million, increased from its prior outlook calling for net product sales of greater than $141 million for the full year. The Company noted that net product sales to date in the fourth quarter have significantly exceeded its prior expectations used in formulating the Company’s outlook provided with its third quarter results on November 8, 2022.
7 PE
Said Dan Peisert, President and Chief Executive Officer of Assertio, “Net product sales in 2022 have consistently exceeded expectations. The revised outlook is driven by better than anticipated volume across the majority of our portfolio, and particularly Indocin. Our recent addition of Sympazan is also generating higher sales than our original projections.”

Recs

1
Member Avatar VladimirPoutine (< 20) Submitted: 2/6/2022 2:43:28 PM : Outperform Start Price: $2.39 NASDAQ:ASRT Score: +77.24

Turn around and highly profitable.

Recs

1
Member Avatar NorthSeaAscend (99.69) Submitted: 7/24/2018 11:30:16 PM : Outperform Start Price: $8.18 NASDAQ:ASRT Score: -96.75

volatile.

Leaderboard

Find the members with the highest scoring picks in ASRT.

Score Leader

zzlangerhans

zzlangerhans (99.70) Score: +420.75

The FDA approval curse claims yet another victim.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
Stormwind 93.11 4/13/2020 Outperform 5Y $0.79 +408.84% +48.10% +360.73 0 Comment
drugtrader 65.37 4/21/2020 Outperform 5Y $0.83 +386.19% +49.71% +336.48 0 Comment
ZeroDotCom 22.77 10/9/2009 Underperform 5Y $5.80 -30.52% +285.20% +315.72 0 Comment
anticitradeshort 26.79 4/20/2009 Underperform NS $2.14 +88.32% +385.22% +296.90 0 Comment
BuyTheDip 22.15 10/13/2009 Underperform 5Y $3.90 +3.33% +282.51% +279.18 0 Comment
joebowler210 88.33 10/14/2009 Underperform 3M $3.73 +8.04% +277.83% +269.79 0 Comment
WorldOnFire 27.02 2/2/2011 Underperform 3W $8.31 -51.50% +215.02% +266.52 0 Comment
reed127 < 20 6/14/2012 Underperform 1Y $4.99 -19.24% +210.40% +229.64 0 Comment
PDTBiotech 50.99 9/28/2012 Underperform NS $5.86 -31.23% +186.10% +217.33 0 Comment
Brxcqqq 23.66 6/14/2007 Underperform 1Y $5.11 -21.14% +184.75% +205.89 3 Comments

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for ASRT.